Skip to main content
Erschienen in: Die Nephrologie 6/2023

13.09.2023 | Chronische Nierenerkrankung | Leitthema

Aktuelle Strategien zur kardiovaskulären Risikoreduktion bei CKD

Was sind rationale und effektive Therapieoptionen zur Senkung des kardiovaskulären Risikos bei chronischen Nierenerkrankungen?

verfasst von: Sammy Patyna, MD, Univ.-Prof. Thimoteus Speer, MD PhD

Erschienen in: Die Nephrologie | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die chronische Nierenerkrankung (CKD) ist mit einer deutlich erhöhten kardiovaskulären Morbidität und Mortalität assoziiert. Begründet ist dies zum einen durch die hohe Prävalenz traditioneller kardiovaskulärer Risikofaktoren bei chronisch Nierenkranken wie arterielle Hypertonie und Diabetes mellitus und zum anderen durch Niereninsuffizienz-spezifische, sog. nichttraditionelle kardiovaskuläre Risikofaktoren. Hierzu gehören v. a. Urämietoxine, urämische Dyslipidämie sowie Inflammation und auch oxidativer Stress.

Ziel der Arbeit

In dieser Übersichtsarbeit fassen wir effektive therapeutische Strategien zur Prävention kardiovaskulärer Ereignisse bei CKD-Patienten zusammen.

Ergebnis

Die Primär- und Sekundärprävention kardiovaskulärer Erkrankungen in der Nephrologie ist von zentraler Bedeutung. Hierzu gehören maßgeblich eine optimale Blutdruck- und Blutzuckereinstellung, die Therapie der Dyslipidämie sowie lebensstilmodifizierende Faktoren wie Gewichtsreduktion und Nikotinkarenz.

Schlussfolgerung

Neue pharmakologische Ansätze, die sowohl die CKD-Progression als auch das kardiovaskuläre Risiko reduzieren, etablieren sich als zentrale Therapiestrategien des CKD-Managements.
Literatur
1.
Zurück zum Zitat Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339–352CrossRefPubMed Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339–352CrossRefPubMed
2.
Zurück zum Zitat Chronic Kidney Disease Prognosis Consortium (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731):2073–2081CrossRef Chronic Kidney Disease Prognosis Consortium (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731):2073–2081CrossRef
3.
Zurück zum Zitat Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV (2015) Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol 26(10):2512–2520CrossRefPubMedPubMedCentral Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV (2015) Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol 26(10):2512–2520CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Drüeke TB, Massy ZA (2010) Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 6(12):723–735CrossRefPubMed Drüeke TB, Massy ZA (2010) Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 6(12):723–735CrossRefPubMed
5.
Zurück zum Zitat Speer T, Ridker PM, von Eckardstein A, Schunk SJ, Fliser D (2021) Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J 42(22):2170–2185CrossRefPubMed Speer T, Ridker PM, von Eckardstein A, Schunk SJ, Fliser D (2021) Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J 42(22):2170–2185CrossRefPubMed
6.
Zurück zum Zitat Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14(1):57–70CrossRefPubMed Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14(1):57–70CrossRefPubMed
7.
Zurück zum Zitat Speer T, Zewinger S, Fliser D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28(10):2456–2463CrossRefPubMed Speer T, Zewinger S, Fliser D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28(10):2456–2463CrossRefPubMed
8.
Zurück zum Zitat Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25(5):1073–1082CrossRefPubMedPubMedCentral Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25(5):1073–1082CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stähli BE et al (2014) Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 35(43):3021–3032CrossRefPubMed Speer T, Owala FO, Holy EW, Zewinger S, Frenzel FL, Stähli BE et al (2014) Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 35(43):3021–3032CrossRefPubMed
10.
Zurück zum Zitat Holy EW, Akhmedov A, Speer T, Camici GG, Zewinger S, Bonetti N et al (2016) Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo. J Am Coll Cardiol 68(15):1664–1676CrossRefPubMed Holy EW, Akhmedov A, Speer T, Camici GG, Zewinger S, Bonetti N et al (2016) Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo. J Am Coll Cardiol 68(15):1664–1676CrossRefPubMed
11.
Zurück zum Zitat Cholesterol Treatment Trialists’ (CTT) Collaboration et al (2016) Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4(10):829–839CrossRef Cholesterol Treatment Trialists’ (CTT) Collaboration et al (2016) Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4(10):829–839CrossRef
12.
Zurück zum Zitat (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383–1389 (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383–1389
13.
Zurück zum Zitat Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335(14):1001–1009CrossRefPubMed Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335(14):1001–1009CrossRefPubMed
14.
Zurück zum Zitat Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696CrossRefPubMed Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696CrossRefPubMed
15.
Zurück zum Zitat Wanner C, Tonelli M et al (2014) KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85(6):1303–1309CrossRefPubMed Wanner C, Tonelli M et al (2014) KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85(6):1303–1309CrossRefPubMed
16.
Zurück zum Zitat Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A et al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397–1408CrossRefPubMed Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A et al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397–1408CrossRefPubMed
17.
Zurück zum Zitat Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL et al (2019) Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol 73(23):2961–2970CrossRefPubMed Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL et al (2019) Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol 73(23):2961–2970CrossRefPubMed
18.
Zurück zum Zitat O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF et al (2022) Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146(15):1109–1119CrossRefPubMed O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF et al (2022) Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146(15):1109–1119CrossRefPubMed
19.
Zurück zum Zitat Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U et al (2020) Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION‑7 and ORION‑1 studies. Mayo Clin Proc 95(1):77–89CrossRefPubMed Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U et al (2020) Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION‑7 and ORION‑1 studies. Mayo Clin Proc 95(1):77–89CrossRefPubMed
20.
Zurück zum Zitat Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388(15):1353–1364CrossRefPubMed Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388(15):1353–1364CrossRefPubMed
21.
Zurück zum Zitat Toth PP, Catapano AL, Helms B, Lei L, Louie MJ, Bakris GL (2022) Safety and efficacy of bempedoic acid in patients with renal impairment. J Am Coll Cardiol 79(9_Supplement):1459–1459CrossRef Toth PP, Catapano AL, Helms B, Lei L, Louie MJ, Bakris GL (2022) Safety and efficacy of bempedoic acid in patients with renal impairment. J Am Coll Cardiol 79(9_Supplement):1459–1459CrossRef
22.
Zurück zum Zitat Klag MJ, Whelton PK, Randall BL, Neaton J, Brancati FL, Ford CE et al (1996) Blood pressure and end-stage renal disease in men. N Engl J Med 334(1):13–18CrossRefPubMed Klag MJ, Whelton PK, Randall BL, Neaton J, Brancati FL, Ford CE et al (1996) Blood pressure and end-stage renal disease in men. N Engl J Med 334(1):13–18CrossRefPubMed
23.
Zurück zum Zitat Habas E, Habas E, Khan FY, Rayani A, Habas A, Errayes M et al (2022) Blood pressure and chronic kidney disease progression: an updated review. Cureus 14(4):e24244PubMedPubMedCentral Habas E, Habas E, Khan FY, Rayani A, Habas A, Errayes M et al (2022) Blood pressure and chronic kidney disease progression: an updated review. Cureus 14(4):e24244PubMedPubMedCentral
24.
Zurück zum Zitat SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116CrossRef SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116CrossRef
25.
Zurück zum Zitat Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL et al (2017) Effects of intensive BP control in CKD. J Am Soc Nephrol 28(9):2812–2823CrossRefPubMedPubMedCentral Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL et al (2017) Effects of intensive BP control in CKD. J Am Soc Nephrol 28(9):2812–2823CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH et al (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3):S1–S87CrossRef Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH et al (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3):S1–S87CrossRef
27.
Zurück zum Zitat Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al (2016) Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67(5):728–741CrossRefPubMed Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al (2016) Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67(5):728–741CrossRefPubMed
28.
Zurück zum Zitat Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E et al (2022) Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 387(22):2021–2032CrossRefPubMed Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E et al (2022) Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 387(22):2021–2032CrossRefPubMed
29.
Zurück zum Zitat Action to Control Cardiovascular Risk in Diabetes Study Group et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559CrossRef Action to Control Cardiovascular Risk in Diabetes Study Group et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559CrossRef
30.
Zurück zum Zitat Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657CrossRefPubMed Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657CrossRefPubMed
31.
Zurück zum Zitat Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334CrossRefPubMed Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334CrossRefPubMed
32.
Zurück zum Zitat Wanner C (2017) EMPA-REG OUTCOME: the nephrologist’s point of view. Am J Med 130(6S):S63–S72CrossRefPubMed Wanner C (2017) EMPA-REG OUTCOME: the nephrologist’s point of view. Am J Med 130(6S):S63–S72CrossRefPubMed
33.
Zurück zum Zitat Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 5(6):632–644CrossRefPubMedPubMedCentral Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci 5(6):632–644CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446CrossRefPubMed Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446CrossRefPubMed
35.
Zurück zum Zitat The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR et al (2023) Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 388(2):117–127CrossRef The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR et al (2023) Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 388(2):117–127CrossRef
36.
Zurück zum Zitat Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ et al (2022) Impact of diabetes on the effects of sodium glucose co-transporter‑2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788–1801CrossRef Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ et al (2022) Impact of diabetes on the effects of sodium glucose co-transporter‑2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788–1801CrossRef
37.
Zurück zum Zitat Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F (2022) Mineralocorticoid receptor antagonists in diabetic kidney disease—Mechanistic and therapeutic effects. Nat Rev Nephrol 18(1):56–70CrossRefPubMed Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F (2022) Mineralocorticoid receptor antagonists in diabetic kidney disease—Mechanistic and therapeutic effects. Nat Rev Nephrol 18(1):56–70CrossRefPubMed
38.
Zurück zum Zitat Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152–161CrossRefPubMed Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152–161CrossRefPubMed
39.
Zurück zum Zitat de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075–3090CrossRefPubMedPubMedCentral de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075–3090CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Ali S, Dave N, Virani SS, Navaneethan SD (2019) Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr Atheroscler Rep 21(9):32CrossRefPubMed Ali S, Dave N, Virani SS, Navaneethan SD (2019) Primary and secondary prevention of cardiovascular disease in patients with chronic kidney disease. Curr Atheroscler Rep 21(9):32CrossRefPubMed
Metadaten
Titel
Aktuelle Strategien zur kardiovaskulären Risikoreduktion bei CKD
Was sind rationale und effektive Therapieoptionen zur Senkung des kardiovaskulären Risikos bei chronischen Nierenerkrankungen?
verfasst von
Sammy Patyna, MD
Univ.-Prof. Thimoteus Speer, MD PhD
Publikationsdatum
13.09.2023
Verlag
Springer Medizin
Erschienen in
Die Nephrologie / Ausgabe 6/2023
Print ISSN: 2731-7463
Elektronische ISSN: 2731-7471
DOI
https://doi.org/10.1007/s11560-023-00686-y

Weitere Artikel der Ausgabe 6/2023

Die Nephrologie 6/2023 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.